ObjectiveThe study aimed was to report 2-year outcomes of endovascular treatment with interwoven nitinol (Supera™) stent for common femoral artery (CFA) lesions.MethodsWe reviewed the clinical data of 20 patients who presented with CFA stenosis or occlusion and underwent balloon angioplasty followed by Supera™ stenting in CFA between February 2016 and January 2022. The outcomes were evaluated in these patients in terms of technical success, post-intervention complications, reintervention, and cumulative patency (1 year, and 2 years).ResultsThe study included 20 patients (22 lesions) who presented with isolated CFA lesions (3), iliac lesions involving CFA (6), superficial femoral artery (SFA) lesions involving CFA (8), and extensive lesions from the iliac artery to SFA (5). There were 16 men (80%) with a mean age of 69.7 years (range, 34–83). Hypertension, smoking, and diabetes were found in 15 (75%), 7 (35%), and 7 patients (35%), respectively. Clinical presentations were Rutherford stage 5 (9, 45%), Rutherford stage 4 (5, 25%), Rutherford stage 6 (4, 20%), and Rutherford stage 3 (2, 10%). Technical success was achieved in all patients (100%). The procedures for treatment were isolated CFA Supera™ stenting (1, 4.5%), CFA plus DFA Supera™ stenting (jailed SFA) (2, 9.1%), CFA plus SFA Supera™ stenting (jailed DFA) (8, 36.4%), CFA Supera™ stenting plus bare iliac stenting (Astron) (6, 27.3%), CFA plus SFA Supera™ stenting (jailed DFA) plus bare iliac stenting (Astron) (5, 22.7%), and additional DFA angioplasty (7, 31.8%). The rate of in-hospital mortality and morbidity were 0% and 10%, respectively. Distal embolization after pre-dilatation occurred in 1 patient, and cerebral infarction occurred 12 h after the procedure in 1 patient. The mean follow-up time was 23 months (range, 2–64). During the follow-up period, in-stent occlusion occurred in 2 patients at 9 and 46 months. Re-intervention was performed in 1 patient due to recurrent symptom of claudication. The cumulative primary patency at 1 year and 2 years were 93.3% and 93.3%, respectively.ConclusionEndovascular treatment with interwoven nitinol (Supera™) stent for CFA lesions was associated with acceptable outcomes at 2 years.

中文翻译：

---

交织镍钛诺支架血管内治疗股总动脉病变：单中心经验的 2 年结果

目的本研究旨在报告交织镍钛诺 (Supera™) 支架血管内治疗治疗股总动脉 (CFA) 病变的 2 年结果。方法我们回顾了 20 名因 CFA 狭窄或闭塞并随后接受球囊血管成形术的患者的临床数据。 2016 年 2 月至 2022 年 1 月期间，在 CFA 中使用 Supera™ 支架置入术。对这些患者的结果进行了评估，包括技术成功、干预后并发症、再干预和累积通畅（1 年和 2 年）。结果该研究包括 20 名患者（22 个病变）表现为孤立的 CFA 病变（3 个）、涉及 CFA 的髂病变（6 个）、涉及 CFA 的股浅动脉（SFA）病变（8 个）以及从髂动脉到 SFA 的广泛病变（5 个）。共有 16 名男性 (80%)，平均年龄为 69.7 岁（范围为 34-83 岁）。分别有 15 名 (75%)、7 名 (35%) 和 7 名 (35%) 患者患有高血压、吸烟和糖尿病。临床表现为 Rutherford 5 期 (9, 45%)、Rutherford 4 期 (5, 25%)、Rutherford 6 期 (4, 20%) 和 Rutherford 3 期 (2, 10%)。所有患者均取得技术成功（100%）。治疗程序为单独的 CFA Supera™ 支架置入术 (1, 4.5%)、CFA 加 DFA Supera™ 支架置入术 (被监禁的 SFA) (2, 9.1%)、CFA 加 SFA Supera™ 支架置入术 (被监禁的 DFA) (8, 36.4%) ，CFA Supera™ 支架加裸髂支架 (Astron) (6, 27.3%)，CFA 加 SFA Supera™ 支架（入狱 DFA）加裸髂支架 (Astron) (5, 22.7%)，以及额外的 DFA 血管成形术 (7, 31.8%）。院内死亡率和发病率分别为0%和10%。1例患者预扩张后发生远端栓塞，1例患者术后12 h发生脑梗死。平均随访时间为 23 个月（范围：2-64 个月）。随访期间，分别有 2 例患者在 9 个月和 46 个月时发生支架内闭塞。1例患者因反复出现跛行症状而再次进行干预。1 年和 2 年累积初次通畅率分别为 93.3% 和 93.3%。 结论 使用交织镍钛诺 (Supera™) 支架治疗 CFA 病变的血管内治疗与 2 年可接受的结果相关。